CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study.

dc.contributor.author

Hu, Shimin

dc.contributor.author

Xu-Monette, Zijun Y

dc.contributor.author

Balasubramanyam, Aarthi

dc.contributor.author

Manyam, Ganiraju C

dc.contributor.author

Visco, Carlo

dc.contributor.author

Tzankov, Alexander

dc.contributor.author

Liu, Wei-min

dc.contributor.author

Miranda, Roberto N

dc.contributor.author

Zhang, Li

dc.contributor.author

Montes-Moreno, Santiago

dc.contributor.author

Dybkær, Karen

dc.contributor.author

Chiu, April

dc.contributor.author

Orazi, Attilio

dc.contributor.author

Zu, Youli

dc.contributor.author

Bhagat, Govind

dc.contributor.author

Richards, Kristy L

dc.contributor.author

Hsi, Eric D

dc.contributor.author

Choi, William WL

dc.contributor.author

Han van Krieken, J

dc.contributor.author

Huang, Qin

dc.contributor.author

Huh, Jooryung

dc.contributor.author

Ai, Weiyun

dc.contributor.author

Ponzoni, Maurilio

dc.contributor.author

Ferreri, Andrés JM

dc.contributor.author

Zhao, Xiaoying

dc.contributor.author

Winter, Jane N

dc.contributor.author

Zhang, Mingzhi

dc.contributor.author

Li, Ling

dc.contributor.author

Møller, Michael B

dc.contributor.author

Piris, Miguel A

dc.contributor.author

Li, Yong

dc.contributor.author

Go, Ronald S

dc.contributor.author

Wu, Lin

dc.contributor.author

Medeiros, L Jeffrey

dc.contributor.author

Young, Ken H

dc.date.accessioned

2019-09-21T21:08:55Z

dc.date.available

2019-09-21T21:08:55Z

dc.date.issued

2013-04

dc.date.updated

2019-09-21T21:08:54Z

dc.description.abstract

CD30, originally identified as a cell-surface marker of Reed-Sternberg and Hodgkin cells of classical Hodgkin lymphoma, is also expressed by several types of non-Hodgkin lymphoma, including a subset of diffuse large B-cell lymphoma (DLBCL). However, the prognostic and biological importance of CD30 expression in DLBCL is unknown. Here we report that CD30 expression is a favorable prognostic factor in a cohort of 903 de novo DLBCL patients. CD30 was expressed in ∼14% of DLBCL patients. Patients with CD30(+) DLBCL had superior 5-year overall survival (CD30(+), 79% vs CD30(-), 59%; P = .001) and progression-free survival (P = .003). The favorable outcome of CD30 expression was maintained in both the germinal center B-cell and activated B-cell subtypes. Gene expression profiling revealed the upregulation of genes encoding negative regulators of nuclear factor κB activation and lymphocyte survival, and downregulation of genes encoding B-cell receptor signaling and proliferation, as well as prominent cytokine and stromal signatures in CD30(+) DLBCL patients, suggesting a distinct molecular basis for its favorable outcome. Given the superior prognostic value, unique gene expression signature, and significant value of CD30 as a therapeutic target for brentuximab vedotin in ongoing successful clinical trials, it seems appropriate to consider CD30(+) DLBCL as a distinct subgroup of DLBCL.

dc.identifier

blood-2012-10-461848

dc.identifier.issn

0006-4971

dc.identifier.issn

1528-0020

dc.identifier.uri

https://hdl.handle.net/10161/19328

dc.language

eng

dc.publisher

American Society of Hematology

dc.relation.ispartof

Blood

dc.relation.isversionof

10.1182/blood-2012-10-461848

dc.subject

Humans

dc.subject

Cyclophosphamide

dc.subject

Vincristine

dc.subject

Doxorubicin

dc.subject

Prednisone

dc.subject

Antigens, CD30

dc.subject

Antineoplastic Agents

dc.subject

Antineoplastic Combined Chemotherapy Protocols

dc.subject

Prognosis

dc.subject

Disease-Free Survival

dc.subject

Treatment Outcome

dc.subject

Multivariate Analysis

dc.subject

Survival Analysis

dc.subject

Follow-Up Studies

dc.subject

Gene Expression Regulation, Neoplastic

dc.subject

Middle Aged

dc.subject

Female

dc.subject

Male

dc.subject

Lymphoma, Large B-Cell, Diffuse

dc.subject

Antibodies, Monoclonal, Murine-Derived

dc.subject

Transcriptome

dc.subject

Rituximab

dc.title

CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study.

dc.type

Journal article

duke.contributor.orcid

Xu-Monette, Zijun Y|0000-0002-7615-3949

duke.contributor.orcid

Young, Ken H|0000-0002-5755-8932

pubs.begin-page

2715

pubs.end-page

2724

pubs.issue

14

pubs.organisational-group

School of Medicine

pubs.organisational-group

Duke

pubs.organisational-group

Pathology

pubs.organisational-group

Clinical Science Departments

pubs.publication-status

Published

pubs.volume

121

Files

Original bundle

Now showing 1 - 2 of 2
Loading...
Thumbnail Image
Name:
39A. 2013 blood, CD30 DLBCL, 03-06-2013.pdf
Size:
748.34 KB
Format:
Adobe Portable Document Format
Loading...
Thumbnail Image
Name:
39B. 2013 Blood, CD30 DLBCL, KHY, 03-06-2013.pdf
Size:
2.49 MB
Format:
Adobe Portable Document Format